Anifrolumab: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

44 citing papers in PubMed, 74 citations in OpenAlex.

1. Contribution of localmBio · 2026
   Article
2. A Novel Use of Anifrolumab for a Novel Disease.ACR open rheumatology · 2026
   Article
3. A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024.Clinical rheumatology · 2026
   Article
4. Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2026
   Review
5. Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026
   Review
6. Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS.BMC rheumatology · 2025
   Article
7. Macrophage-Derived Type 1 IFN, Renal Tubular Epithelial Cell Polyploidization, and AKI-to-CKD Transition.Journal of the American Society of Nephrology : JASN · 2025
   Article
8. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.Signal transduction and targeted therapy · 2025
   Review
9. Macrophages Unmasked: Their Pivotal Role in Driving Atherosclerosis in Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2025
   Review
10. Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus.Lupus science & medicine · 2025
    Article
11. Comprehensive Analysis of TSPAN32 Regulatory Networks and Their Role in Immune Cell Biology.Biomolecules · 2025
    Article
12. Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025
    Article
13. Brain derived β-interferon is a potential player in Alzheimer's disease pathogenesis and cognitive impairment.Alzheimer's research & therapy · 2024
    Article
14. Brain-immune interactions: implication for cognitive impairments in Alzheimer's disease and autoimmune disorders.Journal of leukocyte biology · 2024
    Review
15. Identifying genetic variants that influence the abundance of cell states in single-cell data.Nature genetics · 2024
    Article
16. Advances in Systemic Lupus Erythematosus Treatment With Monoclonal Antibodies: A Mini-Review.Cureus · 2024
    Review
17. Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus.Cureus · 2024
    Review
18. DNA methylation of IFI44L as a potential blood biomarker for childhood-onset systemic lupus erythematosus.Pediatric research · 2024
    Article
19. Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine.Biomolecules · 2024
    Review
20. Mapping theme evolution and identifying hotspots in biomarkers of systemic lupus erythematosus based on global research.Biomarkers in medicine · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as